AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Leveraging machine learning to unravel drug–microbiome interactions in the gut

Ke Wu1,2,Chenya Li1,2,Runming Wang1,2Canyang Zhang1,2Hongya Geng1,2Xuequan Zhou1,2Xiaoming He3Yunfeng Yang4Diannan Lu5Feiran Li1,2( )
Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
Ministry of Education Key Laboratory for Industrial Biocatalysis, Institute of Biochemical Engineering, Department of Chemical Engineering, Tsinghua University, Beijing 100084, China
Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
Institute of Environment and Ecology, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
Department of Chemical Engineering, Tsinghua University, Beijing 100084, China

These authors contributed equally to this work.

Show Author Information

Abstract

The human gut microbiome (HGM) is a complex, highly diverse microbial ecosystem with extensive enzymatic and metabolic capacity. The HGM plays a pivotal role in drug biotransformation, thereby modulating the therapeutic efficacy and pharmacokinetic profiles. Considerable interindividual variability in gut microbiota composition can produce differential metabolic activity, resulting in variable therapeutic responses to the same drug across individuals. In contrast, orally administered drugs can also affect HGM diversity and composition, impacting host health. Despite its importance, the systematic investigation of drug–microbiome interactions (DMIs) presents substantial experimental challenges. In recent years, machine learning (ML) has emerged as a powerful tool in biological and health sciences, offering advanced capabilities in pattern recognition and discovery of hidden relationships. This progress opens new avenues for DMI research. This review provides an overview of recent advances in HGM-mediated drug biotransformation and drug-induced HGM modification, with particular emphasis on ML applications in these areas. We aim to elucidate the critical role of ML in the systematic exploration and mechanistic understanding of DMI, highlighting its importance as a key future research direction.

References

【1】
【1】
 
 
Health Engineering
Article number: 9460012

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wu K, Li C, Wang R, et al. Leveraging machine learning to unravel drug–microbiome interactions in the gut. Health Engineering, 2026, 2: 9460012. https://doi.org/10.26599/HE.2026.9460012

1308

Views

167

Downloads

0

Crossref

Received: 17 June 2025
Revised: 27 September 2025
Accepted: 27 October 2025
Published: 16 April 2026
© The Author(s) 2026. Published by Tsinghua University Press.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the original author(s) and the source, a link to the license is provided, and any changes made are indicated. See (https://creativecommons.org/licenses/by/4.0/)